Lupin Limited (NSE:LUPIN) disclosed on 20 August 2026, via a Regulation 30 filing, that its wholly owned Dutch subsidiary VISUfarma B.V. has entered an Exclusive Licence Agreement with Visus Therapeutics, Inc. (USA) to commercialise YUVEZZI in the European Union, the United Kingdom, Switzerland, Norway, and Iceland, with total potential consideration of up to EUR 75 million.
Key Highlights
- VISUfarma B.V., a wholly owned subsidiary of Lupin, will hold exclusive rights to regulatory activities, commercialisation, marketing, promotion, distribution, and sale of YUVEZZI across the five licensed territories.
- The total potential consideration is up to EUR 75 million, comprising a EUR 20 million strategic investment via a SAFE instrument and up to EUR 55 million in regulatory and commercial milestone payments.
- The agreement runs on a country-by-country basis until the twentieth anniversary of first commercial sale in each country, with VISUfarma holding renewal options of successive five-year periods thereafter.
- Visus Therapeutics is a wholly owned subsidiary of Tenpoint Therapeutics Holding Limited; the transaction is not a related-party transaction and no promoter or promoter-group entity holds any interest in Visus.
About the Company
Lupin Limited (NSE:LUPIN), headquartered in Mumbai, is a global pharmaceutical company with products distributed across more than 100 markets. Its diversified portfolio spans generics, complex generics, specialty medicines, and biosimilars, supported by 15 manufacturing facilities and six research centres. Core therapeutic areas include cardiovascular, respiratory, diabetes, gastrointestinal, and women's health, with a dedicated workforce exceeding 26,000 professionals.
Announcement in Detail
Under the Exclusive Licence Agreement disclosed on 20 August 2026, VISUfarma B.V. acquires the right to commercialise YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%) in the European Union, the United Kingdom, Switzerland, Norway, and Iceland. YUVEZZI is a once-daily, dual-agent eye drop that received U.S. FDA approval for the treatment of presbyopia in adults, a condition characterised by gradual loss of near-vision acuity typically beginning around age 45.
The financial structure of the agreement comprises a EUR 20 million strategic investment by VISUfarma in the capital stock of Visus or its parent entity through a SAFE instrument, providing the right to receive equity upon specified financing or listing events. In addition, up to EUR 55 million in regulatory and commercial milestone payments may become payable, contingent on specified regulatory submissions, approvals, and commercial milestones. The agreement also provides for tiered royalty payments based on net sales and sales milestone payments upon achievement of specified sales thresholds in the licensed territories.
Impact on Investors
Investors will note that the EUR 20 million SAFE investment represents a capital outflow from Lupin's consolidated balance sheet to Visus or its parent entity, with equity conversion contingent on future financing or listing events rather than at a fixed date. The disclosed terms indicate that the remaining EUR 55 million in milestone payments are contingent and will only be triggered upon specified regulatory and commercial achievements; no fixed liability arises on those amounts at this stage.
The filing shows the arrangement extends VISUfarma's ophthalmic commercial footprint, which shareholders will observe aligns with Lupin's stated specialty care strategy. The agreement's country-by-country termination structure and the contingent nature of milestone obligations are terms investors should review in the official exchange filing for a full understanding of the financial commitments involved.
Sector / Market Context
Presbyopia affects approximately 2 billion people globally, according to figures cited by Tenpoint Therapeutics. The European ophthalmic pharmaceuticals market has drawn increasing attention from India-based generic and specialty pharma companies seeking to diversify revenue beyond the U.S. generics segment, where pricing pressure has persisted. YUVEZZI holds U.S. FDA approval, and Tenpoint has filed a Marketing Authorisation Application in the UK via the MHRA's International Recognition Procedure, as stated in the press release accompanying this announcement.